Other languages ACADIA Pharmaceuticals Inc.

Equities

ACAD

US0042251084

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
16.71 ^USD	+2.45%		-0.65%	-46.63%

23/04	Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada	MT
22/04	Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Acadia Pharmaceuticals annonce que la présentation de drogue nouvelle pour la trofinetide dans le traitement du syndrome de Rett a été acceptée pour dépôt et évaluation prioritaire par Santé Canada	22/04
Acadia Pharmaceuticals Inc Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada	22/04
ACADIA Pharmaceuticals Inc. Presents New DAYBUE (trofinetide) Clinical Data at the 2024 American Academy of Neurology Annual Meeting	18/04
ACADIA Pharmaceuticals Inc. Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development	03/04
Acadia Pharmaceuticals Insider Sold Shares Worth $317,081, According to a Recent SEC Filing	28/03
Sector Update: Health Care Stocks Gain Premarket Tuesday	12/03
Aktien New York Ausblick: Gewinne erwartet nach Inflationsdaten	12/03
Consumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-Bell	12/03
Top Premarket Decliners	12/03
Acadia Pharmaceuticals Shares Fall After Late Study of Schizophrenia Drug Fails, Development Ends	12/03
Acadia Pharmaceuticals' schizophrenia drug fails in late-stage study	12/03
Acadia Pharmaceuticals Inc. Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia	12/03
Acadia Pharmaceuticals Q4 Swings to Profit, Revenue Increases -- Shares Fall After Hours	28/02
ACADIA Pharmaceuticals Inc. Provides Sales Guidance for the Full Year 2024	28/02
ACADIA Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
ACADIA Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Culper Research discloses short position in Acadia Pharma	15/02
Acadia Pharmaceuticals Inc. Announces Executive Changes	31/01
Acadia Pharmaceuticals Inc. Announces Management Changes	31/01
Sector Update: Health Care	14/12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages ACADIA Pharmaceuticals Inc.

Equities

ACAD

US0042251084

Other languages

Filters